Bicycle Therapeutics plc: Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,American ,David Borah ,Fay Dufort ,Thomasr Jeffry Evans ,Sarah Sutton ,Lukas Stanczuk ,University Of Glasgow ,Nasdaq ,American Association For Cancer Research ,School Of Cancer Sciences ,Capital Markets Corporate Communications ,Bicycle Therapeutics ,Cancer Research ,Annual Meeting ,Presentation Details ,Immunomodulatory Agents ,Lead Author ,Lia Luus ,First In Human Clinical Trials ,Cancer Sciences ,Bicycle Toxin Conjugate ,Cancer Research United Kingdom Centre ,Bicycle ,Herapeutics ,Present ,023 ,Racr ,Nnual ,Meeting ,